BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 327 filers reported holding BIO-TECHNE CORP in Q4 2018. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $2,495,274 | +11.5% | 32,339 | -1.7% | 0.20% | -5.6% |
Q3 2023 | $2,238,768 | -17.3% | 32,889 | -0.9% | 0.21% | +0.5% |
Q2 2023 | $2,708,287 | -43.7% | 33,178 | +30.8% | 0.21% | -74.2% |
Q1 2020 | $4,808,000 | -22.1% | 25,356 | -9.8% | 0.82% | +4.1% |
Q4 2019 | $6,169,000 | +11.7% | 28,103 | -0.4% | 0.79% | -5.5% |
Q3 2019 | $5,523,000 | -7.0% | 28,226 | -0.9% | 0.84% | +1.2% |
Q2 2019 | $5,940,000 | +11.6% | 28,491 | +6.2% | 0.82% | +19.2% |
Q1 2019 | $5,324,000 | +46.9% | 26,816 | +7.1% | 0.69% | +19.7% |
Q4 2018 | $3,625,000 | -29.6% | 25,048 | -0.7% | 0.58% | -30.4% |
Q3 2018 | $5,147,000 | -15.3% | 25,216 | -38.6% | 0.83% | -12.3% |
Q2 2018 | $6,079,000 | +4.1% | 41,089 | +6.3% | 0.95% | -26.2% |
Q1 2018 | $5,839,000 | +18.4% | 38,655 | +1.5% | 1.28% | -5.2% |
Q4 2017 | $4,932,000 | +5.5% | 38,071 | -1.5% | 1.35% | -8.6% |
Q3 2017 | $4,673,000 | +4.1% | 38,654 | +1.2% | 1.48% | -1.7% |
Q2 2017 | $4,488,000 | +15.6% | 38,194 | -0.0% | 1.51% | +1.6% |
Q1 2017 | $3,883,000 | -1.9% | 38,202 | -0.8% | 1.48% | -14.8% |
Q4 2016 | $3,959,000 | +52.3% | 38,502 | +62.2% | 1.74% | +55.5% |
Q3 2016 | $2,599,000 | -4.6% | 23,738 | -1.7% | 1.12% | -11.3% |
Q2 2016 | $2,723,000 | +17.6% | 24,146 | -1.5% | 1.26% | +8.0% |
Q1 2016 | $2,316,000 | +4.8% | 24,506 | -0.2% | 1.17% | +26.1% |
Q4 2015 | $2,210,000 | -56.0% | 24,556 | -54.8% | 0.93% | -62.6% |
Q3 2015 | $5,019,000 | +8.6% | 54,286 | +15.7% | 2.48% | +14.0% |
Q2 2015 | $4,620,000 | +7.0% | 46,921 | +9.0% | 2.17% | -1.4% |
Q1 2015 | $4,316,000 | +19.0% | 43,036 | +9.7% | 2.20% | +7.3% |
Q4 2014 | $3,626,000 | – | 39,243 | – | 2.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |